|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 3/1/2024
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
|
Cell and Gene Therapies for Hemophagocytic Lymphohistiocytosis
Application
Gene/cell therapy to treat hemophagocytic lymphohistiocytosis.
Key Benefits
Gene therapy approach for treating patients with UNC13D mutated hemophagocytic lymphohistiocytosis.
Preliminary in vitro and in vivo data show the ability of the gene therapy to increase UNC13D protein levels and decrease T cell activation.
It is administered...
Published: 1/17/2024
Contributor(s): H. (Harold) Trent Spencer, Christopher Doering, Shanmuganathan Chandrakasan, Sarah Takushi
|
|
Platform for Transducing Target Cells with a Viral Vector
Application
System for quickly and efficiently obtaining therapeutic levels of transduction.
Key Benefits
Uses less viral vector to achieve high gene transfer.
Shortens transduction time.
Produces clinically relevant gene modified cell numbers.
Market Summary
Information relay at the molecular level, such as the transcription of RNA into proteins,...
Published: 12/1/2023
Contributor(s): Reginald Tran, Wilbur Lam, Christopher Doering, H. (Harold) Trent Spencer
|
|
Microfluidic Device for Increased Viral Transduction Efficiency
Application
Microfluidic chip device for facilitating high throughput viral transduction for gene therapy applications.
Key Benefits
Improves surface-to-volume ratio, allowing more efficient contact between lentiviruses and cells
Increases efficiency while maintaining cell viability of traditional methods.
Enables gene transfer for non-adherent...
Published: 4/8/2024
Contributor(s): Reginald Tran, Wilbur Lam, David Myers, Christopher Doering, H. (Harold) Trent Spencer
|